Literature DB >> 7083728

Sotalol prolongation of the QTc interval in hypertensive patients.

P J Neuvonen, E Elonen, A Tanskanen, J Tuomilehto.   

Abstract

The effect of oral sotalol on the heart rate-corrected AT interval (QTc) was studied in 33 hypertensive patients. Sotalol given once daily in doses of 160 to 640 mg prolonged in QTc interval in a concentration-dependent manner by up to 150 msec (P less than 0.001) over presotalol levels. The prolongation did not correlate with the initial length of the QTc interval. In seven patients with sotalol-prolonged QTc interval, the withdrawal of sotalol for 3 days shortened the interval to nearly its original length. The effect of sotalol of PQ and QRS times was minimal. Sotalol seems to differ from other beta antagonists in having clear amiodarone-like effects on the action potential of the heart after short- and long-term administration. The measuring of the QTc interval is recommended if high school concentrations are expected, since the risk of cardiac arrhythmias may increase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083728     DOI: 10.1038/clpt.1982.122

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

Review 2.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

3.  The role of concentration--effect relationships in the QTc interval prolongation: case sotalol.

Authors:  Pertti J Neuvonen; Erkki Elonen
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

4.  Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting.

Authors:  Keith A Marill; Emily S Miller
Journal:  J Electrocardiol       Date:  2017-02-10       Impact factor: 1.438

Review 5.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

6.  The combined electrophysiological effects of lignocaine and sotalol in canine isolated cardiac Purkinje fibres are rate-dependent.

Authors:  D A Lathrop; A Varró
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 7.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

8.  The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.

Authors:  J M Poirier; P Jaillon; B Lecocq; V Lecocq; A Ferry; G Cheymol
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.